Patent US4673927A successfully refreshed from Google Patents.
EP0138216A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Sustained-release IFN preparation for parenteral administration
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1984-10-12
•
Granted: —
•
Expires: 2004-10-12
Abstract
Abstract A sustained-release preparation of indomethacin, interferon and 4-carbamoyl-imidazolium-5-oleate (SM-108) comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, atelocollagen, gelatin, and a mixture thereof. Said preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.
Inventors
- 👤 Yoshiya Yamahira
- 👤 Keiji Fujioka
- 👤 Shigeji Sato
- 👤 Noboru Yoshida
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 12:02
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/41; A61K31/415; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/212; A61K9/10; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1658; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2063
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
22 words
A sustained-release preparation, which comprises an active ingredient selected from indomethacin interferon and 4-carbamoyl-imidazolium-5-oleate in admixture with a pharmaceutically acceptable biodegradable carrier.
Claim 2
Dependent Claim
22 words
A sustained-release preparation, which comprises an active ingredient selected from indomethacin interferon and 4-carbamoyl-imidazolium-5-oleate in admixture with a pharmaceutically acceptable biodegradable carrier.
Claim 3
Dependent Claim
26 words
The preparation according to claim 1, wherein the biodegradable carrier is a member selected from the group consisting of proteins, polysaccharides and synthetic high molecular compounds.
Claim 4
Dependent Claim
26 words
The preparation according to claim 1, wherein the biodegradable carrier is a member selected from the group consisting of collagen, atelocollagen, gelatin, and a mixture thereof.
Claim 5
Dependent Claim
13 words
The preparation according to claim 1, 2 or 3, wherein interferon is α-interferon.
Claim 6
Dependent Claim
20 words
The preparation according to claim 1, wherein indomethacin is contained in-an amount of 0.5 to 500 mg per dosage unit.
Claim 7
Dependent Claim
23 words
The preparation according to claim 1, wherein interferon is contained in an amount of 10 4 to 10 9 IU per dosage unit.
Claim 8
Dependent Claim
22 words
The preparation according to claim 1, wherein 4-carbamoyl-imidazolium-5-oleate is contained in an amount of 1 mg to 2 g per dosage unit.
Claim 9
Independent Claim
44 words
A method for the preparation of a sustained-release preparation of indomethacin, interferon or 4-carbamoyl-imidazolium-5-oleate, which comprises mixing an aqueous solution of an active ingredient selected from indomethacin, interferon and 4-carbamoyl-imidazolium-5- oleate and a pharmaceutically acceptable biodegradable carrier, and concentrating, spray-dying or lyophilizing the mixture.
Claim 10
Independent Claim
44 words
A method for the preparation of a sustained-release preparation of indomethacin, interferon or 4-carbamoyl-imidazolium-5-oleate, which comprises mixing an aqueous solution of an active ingredient selected from indomethacin, interferon and 4-carbamoyl-imidazolium-5- oleate and a pharmaceutically acceptable biodegradable carrier, and concentrating, spray-dying or lyophilizing the mixture.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.